| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
|
N Engl J Med
|
2004
|
11.86
|
|
2
|
Bivalirudin for patients with acute coronary syndromes.
|
N Engl J Med
|
2006
|
5.49
|
|
3
|
Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
|
N Engl J Med
|
2002
|
4.25
|
|
4
|
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.
|
Lancet
|
2013
|
3.74
|
|
5
|
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
|
Circulation
|
2004
|
3.23
|
|
6
|
Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
|
JAMA
|
2007
|
3.07
|
|
7
|
Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
|
JAMA
|
2002
|
2.73
|
|
8
|
Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.
|
Lancet
|
2007
|
2.67
|
|
9
|
Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial.
|
JAMA
|
2005
|
2.61
|
|
10
|
Relationship between osteoporosis and cardiovascular disease in postmenopausal women.
|
J Bone Miner Res
|
2005
|
2.49
|
|
11
|
Impact of delay to angioplasty in patients with acute coronary syndromes undergoing invasive management: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2010
|
2.15
|
|
12
|
Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.
|
Eur Heart J
|
2007
|
1.92
|
|
13
|
Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial.
|
Circulation
|
2009
|
1.88
|
|
14
|
Prognostic significance of periprocedural versus spontaneously occurring myocardial infarction after percutaneous coronary intervention in patients with acute coronary syndromes: an analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.86
|
|
15
|
Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
1.84
|
|
16
|
Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
|
JAMA
|
2007
|
1.84
|
|
17
|
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial.
|
J Am Coll Cardiol
|
2005
|
1.74
|
|
18
|
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2009
|
1.70
|
|
19
|
Relationship between intravascular ultrasound guidance and clinical outcomes after drug-eluting stents: the assessment of dual antiplatelet therapy with drug-eluting stents (ADAPT-DES) study.
|
Circulation
|
2013
|
1.62
|
|
20
|
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part I.
|
Circulation
|
2005
|
1.60
|
|
21
|
Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries.
|
Circ Cardiovasc Interv
|
2009
|
1.54
|
|
22
|
Prognostic impact of blood transfusion after primary angioplasty for acute myocardial infarction: analysis from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) Trial.
|
JACC Cardiovasc Interv
|
2009
|
1.54
|
|
23
|
Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score.
|
J Am Coll Cardiol
|
2005
|
1.52
|
|
24
|
Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial.
|
Circulation
|
2004
|
1.48
|
|
25
|
Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).
|
Am J Cardiol
|
2005
|
1.47
|
|
26
|
Cost-effectiveness of coronary stenting and abciximab for patients with acute myocardial infarction: results from the CADILLAC (Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications) trial.
|
Circulation
|
2003
|
1.46
|
|
27
|
Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: part II.
|
Circulation
|
2005
|
1.46
|
|
28
|
Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis.
|
JACC Cardiovasc Interv
|
2010
|
1.43
|
|
29
|
Usage patterns and 2-year outcomes with the TAXUS express stent: results of the US ARRIVE 1 registry.
|
Catheter Cardiovasc Interv
|
2008
|
1.42
|
|
30
|
Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection.
|
Eur Heart J
|
2006
|
1.42
|
|
31
|
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
|
Catheter Cardiovasc Interv
|
2008
|
1.38
|
|
32
|
Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction.
|
Circulation
|
2003
|
1.38
|
|
33
|
Impact of baseline platelet count in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction (from the CADILLAC trial).
|
Am J Cardiol
|
2007
|
1.35
|
|
34
|
Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
|
J Am Coll Cardiol
|
2006
|
1.30
|
|
35
|
Usefulness of a cobalt chromium coronary stent alloy.
|
Am J Cardiol
|
2003
|
1.29
|
|
36
|
Randomized comparison of distal protection with a filter-based catheter and a balloon occlusion and aspiration system during percutaneous intervention of diseased saphenous vein aorto-coronary bypass grafts.
|
Circulation
|
2003
|
1.27
|
|
37
|
Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction.
|
Eur Heart J
|
2005
|
1.24
|
|
38
|
Impact of femoral vascular closure devices and antithrombotic therapy on access site bleeding in acute coronary syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial.
|
Circ Cardiovasc Interv
|
2010
|
1.22
|
|
39
|
Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial.
|
J Am Coll Cardiol
|
2004
|
1.21
|
|
40
|
Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
Circulation
|
2005
|
1.19
|
|
41
|
Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial.
|
J Am Coll Cardiol
|
2005
|
1.19
|
|
42
|
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
J Am Coll Cardiol
|
2009
|
1.16
|
|
43
|
Predictors of infarct size after primary coronary angioplasty in acute myocardial infarction from pooled analysis from four contemporary trials.
|
Am J Cardiol
|
2007
|
1.14
|
|
44
|
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.
|
J Am Coll Cardiol
|
2006
|
1.14
|
|
45
|
Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
Circulation
|
2004
|
1.12
|
|
46
|
Percutaneous recanalization of chronically occluded coronary arteries: procedural techniques, devices, and results.
|
Catheter Cardiovasc Interv
|
2005
|
1.12
|
|
47
|
Impact of treatment delays on outcomes of primary percutaneous coronary intervention for acute myocardial infarction: analysis from the CADILLAC trial.
|
Am Heart J
|
2006
|
1.12
|
|
48
|
One-year survival in patients with acute myocardial infarction and a saphenous vein graft culprit treated with primary angioplasty.
|
Am J Cardiol
|
2003
|
1.11
|
|
49
|
Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction.
|
J Am Coll Cardiol
|
2004
|
1.09
|
|
50
|
Magnitude and impact of treatment delays on weeknights and weekends in patients undergoing primary angioplasty for acute myocardial infarction (the cadillac trial).
|
Am J Cardiol
|
2004
|
1.09
|
|
51
|
Impact of smoking status on outcomes of primary coronary intervention for acute myocardial infarction--the smoker's paradox revisited.
|
Am Heart J
|
2005
|
1.08
|
|
52
|
Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
|
JACC Cardiovasc Interv
|
2009
|
1.05
|
|
53
|
Impact of ST-segment resolution after primary angioplasty on outcomes after myocardial infarction in elderly patients: an analysis from the CADILLAC trial.
|
Am Heart J
|
2004
|
1.05
|
|
54
|
Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
J Am Coll Cardiol
|
2004
|
1.04
|
|
55
|
Impact of time to treatment on myocardial reperfusion and infarct size with primary percutaneous coronary intervention for acute myocardial infarction (from the EMERALD Trial).
|
Am J Cardiol
|
2007
|
1.04
|
|
56
|
Impact of body mass index on outcomes after primary angioplasty in acute myocardial infarction.
|
Am Heart J
|
2006
|
1.04
|
|
57
|
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.
|
Breast Cancer Res Treat
|
2012
|
0.96
|
|
58
|
Impact and determinants of left ventricular function in patients undergoing primary percutaneous coronary intervention in acute myocardial infarction.
|
Am J Cardiol
|
2005
|
0.95
|
|
59
|
Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes.
|
J Am Coll Cardiol
|
2008
|
0.94
|
|
60
|
Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
Circulation
|
2003
|
0.92
|
|
61
|
Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
J Am Coll Cardiol
|
2008
|
0.92
|
|
62
|
Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.
|
J Am Coll Cardiol
|
2005
|
0.91
|
|
63
|
Importance of mitral regurgitation inpatients undergoing percutaneous coronary intervention for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
|
J Am Coll Cardiol
|
2004
|
0.91
|
|
64
|
Relation of admission white blood cell count to long-term outcomes after primary coronary angioplasty for acute myocardial infarction (The Stent PAMI Trial).
|
Am J Cardiol
|
2003
|
0.90
|
|
65
|
Impact of collateral flow on myocardial reperfusion and infarct size in patients undergoing primary angioplasty for acute myocardial infarction.
|
Am Heart J
|
2007
|
0.90
|
|
66
|
Relation between leucocyte count, myonecrosis, myocardial perfusion, and outcomes following primary angioplasty.
|
Am J Cardiol
|
2007
|
0.89
|
|
67
|
Contemporary outcomes of rescue percutaneous coronary intervention for acute myocardial infarction: comparison with primary angioplasty and the role of distal protection devices (EMERALD trial).
|
Am Heart J
|
2008
|
0.89
|
|
68
|
Defining the length of stay following percutaneous coronary intervention: an expert consensus document from the Society for Cardiovascular Angiography and Interventions. Endorsed by the American College of Cardiology Foundation.
|
Catheter Cardiovasc Interv
|
2009
|
0.89
|
|
69
|
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
|
JACC Cardiovasc Interv
|
2008
|
0.88
|
|
70
|
Relationship between infarct artery location, epicardial flow, and myocardial perfusion after primary percutaneous revascularization in acute myocardial infarction.
|
Am Heart J
|
2006
|
0.87
|
|
71
|
The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale.
|
Am Heart J
|
2008
|
0.87
|
|
72
|
Prediction of one-year mortality among 30-day survivors after primary percutaneous coronary interventions.
|
Am J Cardiol
|
2006
|
0.87
|
|
73
|
Raloxifene and risk for stroke based on the framingham stroke risk score.
|
Am J Med
|
2009
|
0.87
|
|
74
|
Prognostic implications of creatine kinase elevation after primary percutaneous coronary intervention for acute myocardial infarction.
|
J Am Coll Cardiol
|
2006
|
0.86
|
|
75
|
Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial.
|
J Thromb Thrombolysis
|
2011
|
0.85
|
|
76
|
Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial.
|
J Bone Miner Res
|
2004
|
0.85
|
|
77
|
Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction.
|
Am J Cardiol
|
2005
|
0.85
|
|
78
|
A clinical risk score for prediction of stent thrombosis.
|
Am J Cardiol
|
2008
|
0.84
|
|
79
|
Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis.
|
Am J Cardiol
|
2006
|
0.84
|
|
80
|
Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial.
|
Am Heart J
|
2006
|
0.84
|
|
81
|
Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
|
JACC Cardiovasc Interv
|
2012
|
0.83
|
|
82
|
Usefulness of creatinine clearance in predicting early and late death after primary angioplasty for acute myocardial infarction.
|
Am J Cardiol
|
2003
|
0.83
|
|
83
|
Prospective, multicenter study of thrombectomy in patients with acute myocardial infarction: the X-Tract AMI registry.
|
J Interv Cardiol
|
2007
|
0.82
|
|
84
|
Does proximal location of culprit lesion confer worse prognosis in patients undergoing primary percutaneous coronary intervention for ST elevation myocardial infarction?
|
J Interv Cardiol
|
2006
|
0.82
|
|
85
|
Effect of Raloxifene on all-cause mortality.
|
Am J Med
|
2010
|
0.82
|
|
86
|
Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
|
Am J Cardiol
|
2004
|
0.81
|
|
87
|
Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme.
|
EuroIntervention
|
2009
|
0.81
|
|
88
|
Relation between late patency of the infarct-related artery, left ventricular function, and clinical outcomes after primary percutaneous intervention for acute myocardial infarction (CADILLAC trial).
|
Am J Cardiol
|
2004
|
0.80
|
|
89
|
A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients.
|
EuroIntervention
|
2011
|
0.80
|
|
90
|
Are adverse events following an invasive strategy in patients with non-ST-segment elevation acute coronary syndromes more frequent at US sites versus non-US sites? Analysis from the ACUITY trial.
|
Catheter Cardiovasc Interv
|
2013
|
0.79
|
|
91
|
Prospective, randomized evaluation of thrombectomy prior to percutaneous intervention in diseased saphenous vein grafts and thrombus-containing coronary arteries.
|
J Am Coll Cardiol
|
2003
|
0.79
|
|
92
|
Outcomes following bail-out abciximab administration during primary intervention in acute myocardial infarction (The CADILLAC Trial).
|
Am J Cardiol
|
2003
|
0.79
|
|
93
|
Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial).
|
Am J Cardiol
|
2003
|
0.79
|
|
94
|
Long-term paclitaxel-eluting stent outcomes in elderly patients.
|
Circ Cardiovasc Interv
|
2009
|
0.79
|
|
95
|
Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors.
|
Am J Cardiol
|
2006
|
0.79
|
|
96
|
Antiplatelet therapy use and the risk of venous thromboembolic events in the Raloxifene Use for the Heart (RUTH) trial.
|
J Womens Health (Larchmt)
|
2010
|
0.77
|
|
97
|
Two-year results of paclitaxel-eluting stents in patients with medically treated diabetes mellitus from the TAXUS ARRIVE program.
|
Am J Cardiol
|
2009
|
0.77
|
|
98
|
Comparison of coronary stenting versus conventional balloon angioplasty on five-year mortality in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
|
Am J Cardiol
|
2005
|
0.76
|
|
99
|
Outcomes of patients consented but not randomized in a trial of primary percutaneous coronary intervention in acute myocardial infarction (the CADILLAC registry).
|
Am J Cardiol
|
2005
|
0.76
|
|
100
|
Two-Year outcomes after utilization of the TAXUS paclitaxel-eluting stent in bifurcations and multivessel stenting in the ARRIVE registries.
|
J Interv Cardiol
|
2011
|
0.76
|
|
101
|
Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass.
|
Menopause
|
2012
|
0.75
|
|
102
|
Correlations between epicardial flow, microvascular reperfusion, infarct size and clinical outcomes in patients with anterior versus non-anterior myocardial infarction treated with primary or rescue angioplasty: analysis from the EMERALD trial.
|
EuroIntervention
|
2009
|
0.75
|
|
103
|
Implications of pre-procedural TIMI flow in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary revascularization: insights from the ACUITY trial.
|
Int J Cardiol
|
2012
|
0.75
|
|
104
|
Outcomes after implantation of the TAXUS paclitaxel-eluting stent in saphenous vein graft lesions: results from the ARRIVE (TAXUS Peri-Approval Registry: A Multicenter Safety Surveillance) program.
|
JACC Cardiovasc Interv
|
2010
|
0.75
|
|
105
|
Influence of admission and discharge aspirin use on survival after primary coronary angioplasty for acute myocardial infarction.
|
Am J Cardiol
|
2004
|
0.75
|
|
106
|
Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.
|
J Interv Cardiol
|
2009
|
0.75
|
|
107
|
Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme.
|
EuroIntervention
|
2011
|
0.75
|
|
108
|
Safety and efficacy of a novel device for treatment of thrombotic and atherosclerotic lesions in native coronary arteries and saphenous vein grafts: results from the multicenter X-Sizer for treatment of thrombus and atherosclerosis in coronary applications trial (X-TRACT) study.
|
Catheter Cardiovasc Interv
|
2003
|
0.75
|
|
109
|
Two-year clinical outcomes with paclitaxel-eluting coronary stents in patients with chronic total occlusions: analysis from the TAXUS ARRIVE program.
|
J Interv Cardiol
|
2011
|
0.75
|
|
110
|
Comparison of catheterization laboratory initiated abciximab and eptifibatide during percutaneous coronary intervention in acute coronary syndromes (an ACUITY substudy).
|
Am J Cardiol
|
2010
|
0.75
|
|
111
|
Implications of myocardial reperfusion on survival in women versus men with acute myocardial infarction undergoing primary coronary intervention.
|
Am J Cardiol
|
2013
|
0.75
|
|
112
|
Variation in hospital length of stay in patients with acute myocardial infarction undergoing primary angioplasty and the need to change the diagnostic-related group system.
|
Am J Cardiol
|
2003
|
0.75
|
|
113
|
Influence of vessel diameter on the efficacy of distal protection devices during saphenous vein graft intervention.
|
Am J Cardiol
|
2005
|
0.75
|
|
114
|
Outcomes of bail-out stenting for suboptimal balloon angioplasty during primary intervention in acute myocardial infarction (The CADILLAC trial).
|
Am J Cardiol
|
2003
|
0.75
|